Ascendis continued big investments into 2021, driving operating deficit up
Ramped up investing into sales and research helped drive up the operational deficit at biotech firm Ascendis Pharma. Even so, the company’s 2021 growth matched that of recent years.
by ANDREAS LØNSTRUP, translated by daniel pedersen
Danish biotech company Ascendis Pharma, which is listed in the US, continued on its growth track in 2021, booking a revenue of EUR 7.8m compared to preceding year’s EUR 7.8m, the company’s full-year report states.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers
